Bruce R Lawford1, Mark Barnes2, C Phillip Morris3, Ernest P Noble4, Phillip Nyst2, Karen Heslop5, Ross McD Young3, Joanne Voisey3, Jason P Connor6. 1. Division of Mental Health, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Brisbane, Queensland, Australia bruce.lawford@health.qld.gov.au. 2. Division of Mental Health, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia. 3. Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Brisbane, Queensland, Australia. 4. Alcohol Research Center, Neuropsychiatric Institute, University of California, Los Angeles, CA, USA. 5. Faculty of Health Sciences, Curtain University, Perth, Western Australia, Australia. 6. Department of Psychiatry and Centre for Youth Substance Abuse Research, The University of Queensland, Herston, Brisbane, Queensland, Australia.
Abstract
OBJECTIVE: Type 2 diabetes is commonly found in schizophrenia and is an important contributor to mortality and morbidity in this condition. Dopamine has been implicated in the aetiology of both diabetes and schizophrenia. It is possible that both disorders share a common genetic susceptibility. METHODS: In a cross-sectional study, we examined 2 dopamine D2 receptor (DRD2) single-nucleotide polymorphisms (SNPs) previously associated with schizophrenia (C939 T, rs6275 and C957 T, rs6277) along with fasting blood glucose and body mass index (BMI) in 207 antipsychotic-treated patients with schizophrenia. All participants met DSM-IV criteria for schizophrenia, and those with other psychiatric disorders were excluded. Analysis of covariance was used to compare fasting glucose results by DRD2 genotypes, after controlling for known confounds. For significant associations, follow-up Bonferroni post hoc tests examined differences in fasting glucose levels between genotypes. Specific comparisons were also made using analysis of variance and chi-square (Fisher's exact test). RESULTS: The 2 DRD2 risk genotypes were associated with significant increases in blood glucose, after controlling for BMI, age, sex, dosage and type of antipsychotic medication, number of hospitalisations, and negative symptoms (rs6275, F(2, 182) = 5.901, P = 0.003; rs6277 SNP, F(2, 178) = 3.483, P = 0.033). CONCLUSIONS: These findings support the involvement of DRD2 not only in schizophrenia but also in elevated levels of blood glucose commonly found in antipsychotic-treated patients with schizophrenia. Our data support the notion that diabetes may not merely be a comorbid condition but could be fundamentally associated with the pathogenesis of schizophrenia itself.
OBJECTIVE: Type 2 diabetes is commonly found in schizophrenia and is an important contributor to mortality and morbidity in this condition. Dopamine has been implicated in the aetiology of both diabetes and schizophrenia. It is possible that both disorders share a common genetic susceptibility. METHODS: In a cross-sectional study, we examined 2 dopamine D2 receptor (DRD2) single-nucleotide polymorphisms (SNPs) previously associated with schizophrenia (C939 T, rs6275 and C957 T, rs6277) along with fasting blood glucose and body mass index (BMI) in 207 antipsychotic-treated patients with schizophrenia. All participants met DSM-IV criteria for schizophrenia, and those with other psychiatric disorders were excluded. Analysis of covariance was used to compare fasting glucose results by DRD2 genotypes, after controlling for known confounds. For significant associations, follow-up Bonferroni post hoc tests examined differences in fasting glucose levels between genotypes. Specific comparisons were also made using analysis of variance and chi-square (Fisher's exact test). RESULTS: The 2 DRD2 risk genotypes were associated with significant increases in blood glucose, after controlling for BMI, age, sex, dosage and type of antipsychotic medication, number of hospitalisations, and negative symptoms (rs6275, F(2, 182) = 5.901, P = 0.003; rs6277 SNP, F(2, 178) = 3.483, P = 0.033). CONCLUSIONS: These findings support the involvement of DRD2 not only in schizophrenia but also in elevated levels of blood glucose commonly found in antipsychotic-treated patients with schizophrenia. Our data support the notion that diabetes may not merely be a comorbid condition but could be fundamentally associated with the pathogenesis of schizophrenia itself.
Authors: Elitza T Betcheva; Taisei Mushiroda; Atsushi Takahashi; Michiaki Kubo; Sena K Karachanak; Irina T Zaharieva; Radoslava V Vazharova; Ivanka I Dimova; Vihra K Milanova; Todor Tolev; George Kirov; Michael J Owen; Michael C O'Donovan; Naoyuki Kamatani; Yusuke Nakamura; Draga I Toncheva Journal: J Hum Genet Date: 2009-01-16 Impact factor: 3.172
Authors: R Rodriguez-Jimenez; J Hoenicka; M A Jimenez-Arriero; G Ponce; A Bagney; M Aragues; T Palomo Journal: Neuropsychobiology Date: 2007-01-17 Impact factor: 2.328
Authors: Albert H Kim; Erin K Parker; Vernell Williamson; Gowon O McMichael; Ayman H Fanous; Vladimir I Vladimirov Journal: Schizophr Res Date: 2012-08-09 Impact factor: 4.939
Authors: Jubao Duan; Mark S Wainwright; Josep M Comeron; Naruya Saitou; Alan R Sanders; Joel Gelernter; Pablo V Gejman Journal: Hum Mol Genet Date: 2003-02-01 Impact factor: 6.150
Authors: B Guigas; J E de Leeuw van Weenen; N van Leeuwen; A M Simonis-Bik; T W van Haeften; G Nijpels; J J Houwing-Duistermaat; M Beekman; J Deelen; L M Havekes; B W J H Penninx; N Vogelzangs; E van 't Riet; A Dehghan; A Hofman; J C Witteman; A G Uitterlinden; N Grarup; T Jørgensen; D R Witte; T Lauritzen; T Hansen; O Pedersen; J Hottenga; J A Romijn; M Diamant; M H H Kramer; R J Heine; G Willemsen; J M Dekker; E M Eekhoff; H Pijl; E J de Geus; P E Slagboom; L M 't Hart Journal: Diabet Med Date: 2014-05-02 Impact factor: 4.359
Authors: Caroline Davis; Robert D Levitan; Zeynep Yilmaz; Allan S Kaplan; Jacqueline C Carter; James L Kennedy Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2012-05-08 Impact factor: 5.067
Authors: Teodor T Postolache; Laura Del Bosque-Plata; Serge Jabbour; Michael Vergare; Rongling Wu; Claudia Gragnoli Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2019-02-06 Impact factor: 3.568
Authors: Anne Marie Greenhalgh; Leticia Gonzalez-Blanco; Clemente Garcia-Rizo; Emilio Fernandez-Egea; Brian Miller; Miguel Bernardo Arroyo; Brian Kirkpatrick Journal: Schizophr Res Date: 2016-10-17 Impact factor: 4.939
Authors: Marie-Luise Bouvier; Karin Fehsel; Andrea Schmitt; Eva Meisenzahl-Lechner; Wolfgang Gaebel; Martina von Wilmsdorff Journal: Brain Behav Date: 2020-06-11 Impact factor: 2.708
Authors: Kenneth Blum; Thomas McLaughlin; Abdalla Bowirrat; Edward J Modestino; David Baron; Luis Llanos Gomez; Mauro Ceccanti; Eric R Braverman; Panayotis K Thanos; Jean Lud Cadet; Igor Elman; Rajendra D Badgaiyan; Rehan Jalali; Richard Green; Thomas A Simpatico; Ashim Gupta; Mark S Gold Journal: J Pers Med Date: 2022-02-21
Authors: Diana Z Paderina; Anastasiia S Boiko; Ivan V Pozhidaev; Irina A Mednova; Anastasia A Goncharova; Anna V Bocharova; Olga Yu Fedorenko; Elena G Kornetova; Arkadiy V Semke; Nikolay A Bokhan; Anton J M Loonen; Svetlana A Ivanova Journal: Genes (Basel) Date: 2022-07-23 Impact factor: 4.141